Back

Abingworth raises $582 million for new Clinical Co-Development Fund – Over $1 billion raised in 2021 for two funds

  • Written By: Asante Capital

Asante Capital are pleased to announce the final closing of Abingworth’s new Clinical Co-Development Fund at $582 million. Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of $350 million and closing at its hard cap. Alongside the recent $465 million Abingworth Bioventures (ABV 8) flagship fund, Abingworth has raised over $1 billion to invest in life science companies in the US, UK and Continental Europe developing innovative therapeutics with potential to significantly improve human health.

Asante Capital Group acted as global placement advisor for the fundraise.

Please see full Press Release here.

To read more on the Times click here.

Artá Capital races to first close with commitments of €305m on a target of €400m

We are pleased to announce that Artá Capital Partners (“Artá”), a leading Iberian private equity firm, has raised over three quarters of their €400m target at the first close of Artá Capital Fund III LP (“Fund III”).

Winner at Private Equity Wire Awards 2023

We are honoured to be named Best Placement Agent as part of Private Equity Wire’s European Awards 2023! Winners were selected based on performance data and industry voting.

Asante Capital Solutions – Q4 2022 Newsletter

Following a decade of robust and unprecedented growth in the Asia-Pacific private equity region, 2022 brought with it a combination of challenges, ranging from the lingering effects of the COVID pandemic, global economic downturn and general macro uncertainty, casting a dark cloud over the region’s private markets. The answer to what the market in 2023 will look like is multi-faceted: in this newsletter, we are putting a spotlight on the key trends we are seeing in the APAC region and assessing their impact on the fundraising landscape.
Back to top
© Asante 2023
Design by Firedog